1. Academic Validation
  2. Fe-doped phase-transition nanodroplets for synergistic photothermal and starvation-enhanced ferroptosis in cancer therapy

Fe-doped phase-transition nanodroplets for synergistic photothermal and starvation-enhanced ferroptosis in cancer therapy

  • J Nanobiotechnology. 2025 Oct 16;23(1):684. doi: 10.1186/s12951-025-03726-y.
Yuhang Tian # 1 Xiang He # 2 Yanchi Yuan 1 Chunyue Wang 1 Mengchi Zhang 3 Hui Jiang 3 Huajing Yang 1 Kuikun Yang 4 Hui Jing 5 6
Affiliations

Affiliations

  • 1 Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, 150080, China.
  • 2 Department of Ultrasound, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150080, China.
  • 3 School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.
  • 4 School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China. yangkuikun@hit.edu.cn.
  • 5 Department of Ultrasound, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150080, China. jinghuihrb@163.com.
  • 6 Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, 150080, China. jinghuihrb@163.com.
  • # Contributed equally.
Abstract

Background: Ferroptosis therapy has emerged as a promising antitumor strategy by utilizing the Fenton reaction to destroy Cancer cells, where Fe2+ catalyzes the decomposition of H2O2 into hydroxyl radicals (•OH). Despite the great potential of Ferroptosis therapy in suppressing tumor growth, inadequate catalysts and reactants within tumors remains a major challenge before its clinical translation. Herein, we developed glucose oxidase (GOx)-loaded phase-transition nanodroplets (PND) modified with Fe-tannic acid (TA) networks (PND@GOx@Fe-TA) for enhanced antitumor efficacy of Ferroptosis therapy via synergistic photothermal and starvation therapy.

Results: PND@GOx@Fe-TA can convert glucose into H2O2, which not only provides sufficient H2O2 for Fenton reaction, but also consumes glucose to exert starvation therapy. In addition, the Fe-TA networks of PND@GOx@Fe-TA can be degraded upon reaching the tumor site, thus generating Fe2+ from Fe3+ via reduction by the overexpressed glutathione (GSH) in the tumor microenvironment. The Fe2+ then reacts with the in situ-generated H2O2 for enhanced Fenton reaction and induces Ferroptosis of Cancer cells. Additionally, the PND@GOx@Fe-TA exhibits photothermal effects under 808 nm laser irradiation, which not only accelerates the Fe2+-mediated Fenton reaction but also gasifies the liquid core of the PND, enabling its use as a contrast agent for contrast-enhanced ultrasound (CEUS), photoacoustic imaging (PAI) and magnetic resonance imaging (MRI).

Conclusions: In summary, the PND@GOx@Fe-TA represents a promising approach for multimodal imaging-guided antitumor therapy by synergistic starvation, photothermal and enhanced Ferroptosis therapy.

Keywords

Ferroptosis therapy; Glucose oxidase; Phase-transition nanodroplets; Photothermal therapy; Starvation therapy.

Figures
Products